Dasatinib versus nilotinib as upfront therapy for treatment naïve chronic myeloid leukemia chronic phase
<p>This is a randomized, phase 3 clinical trial comparing ’head to head’ nilotinib versus dasatinib as upfront therapy for patient with chronic myeloid leukemia. The efficacy of both drugs will be tested by measuring BCR/ABL using European LeukemiaNet recommendations. The study will be conduct...
محفوظ في:
| المؤلف الرئيسي: | Mohamed A. Yassin (16322749) (author) |
|---|---|
| مؤلفون آخرون: | Anas A. Hamad (16515247) (author), Radwa M. Hussein (16515249) (author), Ahmed M. Basha (16515250) (author), Ahmad M. Adel (16515253) (author), Prem Chandra (9072038) (author), Abdulqadir J. Nashwan (16328993) (author) |
| منشور في: |
2021
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors
حسب: Mohamed A. Ismail (418629)
منشور في: (2022) -
Myelomastocytic transformation in chronic myeloid leukemia blast phase: A case report
حسب: Abdulrahman F. Al-Mashdali (17148316)
منشور في: (2025) -
Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies
حسب: Salma Younes (6424865)
منشور في: (2023) -
Gene Expression Landscape of Chronic Myeloid Leukemia K562 Cells Overexpressing the Tumor Suppressor Gene PTPRG
حسب: Giulia Lombardi (3944720)
منشور في: (2022) -
Safety and efficacy of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia: A protocol for systematic review and meta-analysis
حسب: Fateen Ata (12217764)
منشور في: (2022)